PQ Bypass Announces $60 Million Financing to Advance New Therapeutic Approach to Peripheral Arterial Disease – Business Wire

SUNNYVALE, Calif.–()–PQ Bypass, Inc., a medical device company dedicated to advancing
treatment options for patients with peripheral arterial disease (PAD),
has entered into an agreement that provides for up to an aggregate of
$60 million in equity financing, led by Deerfield Management. Joining
the round are existing investors, including Seroba Life Sciences and
MedTech Venture Partners. The financing round also allowed the company
to convert approximately $15 million in outstanding convertible debt and
interest to equity. Funds will be used to advance the clinical
development of the company’s technology for the treatment of long
blockages in leg arteries caused by PAD.

“With this funding we continue our pursuit of the science that will
bring us closer to commercial release of this important advancement in
the care of patients with PAD,” said Richard Ferrari, Chairman and Chief
Executive Officer of PQ Bypass. “We are very fortunate to have Deerfield
as an anchor investor and, together, we are working to develop a
minimally-invasive treatment alternative for a disease that affects
millions of people, worldwide.”

In people with PAD, leg arteries can become blocked by long segments of
plaque that restrict blood flow to the lower leg and foot. This can lead
to pain, loss of mobility and even amputation. Extremely long blockages,
such as those greater than 20 centimeters, are quite challenging to
treat. Historically, physicians have performed open bypass surgery,
which has the benefit of durability; however, it is associated with an
increased risk of complications, lengthy hospital stays and prolonged
rehabilitation. Minimally invasive approaches, including angioplasty and
stenting, work very well on shorter blockages; however, they have not
been as effective on longer ones, often resulting in repeat procedures
within one year.

Percutaneous femoropopliteal bypass (the DETOUR procedure) is designed
to provide the durability of open bypass with the benefits of a
minimally-invasive approach. In this procedure, PQ Bypass’ proprietary
stent graft technology is placed from the superficial femoral artery,
into the femoral vein, and back into the popliteal artery to create a
detour around the blockage. The stent graft bypass re-directs
oxygen-rich blood, with the goal of restoring blood flow to the lower
leg and foot of the patient.

“PQ Bypass has developed a novel technology and procedure to address a
true clinical conundrum in the treatment of long lesions from PAD. This
technology has the potential to be the standard of care for the segment
of PAD patients who, today, have to choose between either an open
surgical treatment that lasts longer or less-invasive treatment options
that potentially fail approximately 50% of the time. In addition to
improving outcomes for patients, this has the potential to significantly
reduce the cost burden of long lesion PAD,” said Andrew ElBardissi,
M.D., of Deerfield.

About Peripheral Artery Disease (PAD)

Peripheral Artery Disease, or PAD, is a common but serious circulatory
condition wherein adequate blood flow does not reach the limbs due to a
build-up of fatty deposits and calcium on the artery walls. If severe
enough, blocked blood flow can cause tissue death and can sometimes lead
to amputation of the foot or leg.

Lower extremity PAD is the third leading cause of atherosclerotic
cardiovascular morbidity, following coronary artery disease and stroke.
Systematic reviews indicate that PAD affects over 200 million people
worldwide—and the prevalence of PAD is increasing as “baby boomers”
enter high-risk age groups. With estimates of more than 20% of the
population projected to age into the 65-and-over cohort by the year
2050, PAD is a growing epidemic with staggering social and economic

About the DETOUR II Trial

The DETOUR II trial is the first and only pivotal investigational trial
in the United States for percutaneous bypass. Currently underway, the
trial will enroll up to 292 patients at up to 40 sites across the United
States and Europe, and is led by national co-Principal Investigators
Sean Lyden, MD, FACS and Chairman of the Department of
Vascular Surgery at the Cleveland Clinic, and Jihad Mustapha, MD, FACC,
FSCAI, CEO at Advanced Cardiac and Vascular Amputation Prevention
Centers. The DETOUR II trial aims to expand the body of evidence
evaluating the safety and effectiveness of the DETOUR System to create a
percutaneous femoropopliteal bypass. More details can be found at
clinicaltrials.gov, trial identifier NCT03119233.

About Deerfield Management Company

Deerfield is an investment management firm committed to advancing
healthcare through investment, information and philanthropy. For more
information about Deerfield, visit www.deerfield.com.

About PQ Bypass

PQ Bypass is operated by recognized leaders in the medical device
industry including veterans from Medtronic, Abbott, Johnson & Johnson,
and Stryker. The underlying technology and technique used in the DETOUR
percutaneous femoropopliteal bypass procedure were co-developed by two
world-renowned cardiologists and innovators, Dr. James Joye and Dr.
Richard Heuser, who are recognized experts in peripheral artery disease.

In March 2017, PQ Bypass received CE (Conformité Européenne) Mark
approval for the DETOUR™ System.

In August 2017, Frost & Sullivan recognized PQ Bypass with the 2017
European PAD Interventions Technology Innovation Award for the DETOUR

The DETOUR™ System is an investigational device and is limited by United
States law to investigational use only. It is not available for sale.
For more information, please visit www.pqbypass.com.

Source link

Leave a Reply

Your email address will not be published.